20 articles
Peter Attia dissects the null results of the MET-PREVENT trial and what they reveal about the hard science of testing aging interventions.
Breakthrough research reveals metformin works through the brain, not just the liver, opening new doors for diabetes treatment.
Two popular longevity drugs show evidence of interfering with the body's response to exercise โ a critical tradeoff for active users.
A landmark 21-year trial finds diet and exercise interventions cut multimorbidity risk by 21% in prediabetic adults โ metformin showed no such benefit.
Cambrian Bio's ATX-304 reduced liver fat, visceral fat, and raised resting metabolic rate by 8% in a Phase 1b trial of adults with prediabetes.
Cambrian Bio's ATX-304 combines AMPK and mitochondrial activation in a pill form, with Phase 1b data in prediabetic obese adults due this week.
Geroscience pioneer Dr Nir Barzilai explains how intervening in aging biology โ not individual diseases โ may be medicine's biggest leap.
ATX-304 raised resting metabolic rate 8%, slashed triglycerides, and reduced liver fat in an 8-week Phase 1b trial for prediabetes.
Dr. Nir Barzilai outlines existing FDA-approved drugs with geromedicine potential and shares insights from decades of centenarian research.
A single FGF21 gene injection in aging mice extended median lifespan by 20%, reversing fat gain, inflammation, and organ decline.
A major RCT shows finerenone reduces kidney function loss by 23% in non-diabetic CKD patients, expanding its protective role beyond diabetes.
A novel ฮฒ2 agonist pill boosts fat burning via skeletal muscle, preserving muscle mass while improving blood sugar in early trials.
Seragon's oral combo therapy SRN-901 outperforms rapamycin in mice, boosting lifespan and slashing frailty through multi-pathway aging intervention.
GSK acquires 35Pharma for $950M, gaining a drug that may treat lung disease while also improving insulin sensitivity and preserving muscle.
New research links metabolomic aging, smoking cessation, and repurposed drugs to dementia risk โ plus estrogen's role in post-menopausal memory loss.
Preclinical mouse data suggests semaglutide cycling may trigger sarcopenia in later life, raising questions about long-term body composition effects.
A 20,000-person study finds IgG glycan patterns track biological aging, predict mortality, and shift toward youth with interventions.
New research shows targeting ghrelin receptors improves muscle function and reduces sarcopenia in aging mice through better mitochondrial health.
Junevity's GalNAc siRNA candidate restores healthier gene expression in diabetic mice with no safety signals, targeting cardiometabolism and neurodegeneration.
New research links exercise timing to your body clock, confirms oral GLP-1 heart safety, and flags prediabetes as an AFib risk factor.
